The Novel mTOR Complex 1/2 Inhibitor P529 Inhibits Human Lung Myofibroblast Differentiation. Issue 8 (18th April 2017) - Ferguson, Keith T.
ABSTRACT: Idiopathic pulmonary fibrosis is a progressive and deadly disorder with very few therapeutic options. Palomid 529 (8‐(1‐hydroxyethyl)‐2‐methoxy‐3‐(4‐methoxybenzyloxy)‐benzo[c]chromen‐6‐one; P529) is a novel dual inhibitor of mechanistic target of rapamycin complex 1/2 (mTORC1/2). In these studies, we investigated the effect of P529 on TGF‐β‐dependent signaling and myofibroblast differentiation. TGF‐β‐induced phosphorylation of the mTORC1 targets, p70 S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E‐BP1), were both dose dependently inhibited by P529 in human lung fibroblasts with maximal inhibition occurring between 10 and 20 μM. mTORC2‐mediated phosphorylation of Akt at the S473 site was partially inhibited with a similar dose dependency, as was TGF‐β‐induced myofibroblast differentiation. Protein levels of TGF‐β‐induced fibronectin and collagen were similarly decreased by P529. At this dose, there was also inhibition of mRNA transcript levels for Col1 and α‐SMA, suggesting inhibition of transcriptional activation. However, there was no effect of P529 on canonical TGF‐β‐induced Smad signaling, as assessed by receptor‐associated Smad2/3 phosphorylation, Smad2/3/4 translocation, or Smad‐driven gene expression, as assessed by Smad‐binding element driven luciferase. Conversely, activation of mTORC1/2 signaling was dependent on TGF‐β type I receptor (ALK5) signaling and on Smad2/3 expression. P529 treatment disrupted TGF‐β‐induced actin stress fiber formation during myofibroblast differentiation, the deposition of new extracellular fibronectin matrix, and linear wound closure by fibroblasts. Likewise, mTOR knockdown inhibited TGF‐β‐induced myofibroblast differentiation. In conclusion, P529 inhibits TGF‐β‐induced myofibroblast differentiation, actin stress fiber formation, and matrix protein expression and deposition. Inhibition of mTORC1/2 by P529 may be a promising approach to inhibit in vivo fibrosis. J. Cell. Biochem. 118: 2241–2249, 2017. © 2017 Wiley Periodicals, Inc. Abstract : We investigated the effect of the dual mechanistic target of rapamycin complex 1/2 (mTORC1/2) inhibitor Palomid 529 (P529) on TGF‐β‐dependent signaling and myofibroblast differentiation. TGF‐β‐induced mTORC1/2 signaling and myofibroblast differentiation were inhibited by P529, independent of SMAD‐signaling. Treatment with P529 resulted in loss of actin stress fiber formation and fibronectin deposition by fibroblasts, suggesting that P529 may be an effective antifibrotic therapy in vivo.